On Tuesday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened lower -2.87% from the last session, before settling in for the closing price of $9.77. Price fluctuations for OCUL have ranged from $2.88 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 121.20%. Company’s average yearly earnings per share was noted -15.59% at the time writing. With a float of $135.46 million, this company’s outstanding shares have now reached $156.65 million.
Considering the fact that the conglomerate employs 267 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 13.84%, while institutional ownership is 77.39%. The most recent insider transaction that took place on Nov 25 ’24, was worth 26,561. In this transaction Chief Scientific Officer of this company sold 2,948 shares at a rate of $9.01, taking the stock ownership to the 269,059 shares. Before that another transaction happened on Nov 25 ’24, when Company’s Chief Development Officer sold 2,897 for $9.01, making the entire transaction worth $26,102. This insider now owns 213,087 shares in total.
Ocular Therapeutix Inc (OCUL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -15.59% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.06 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Compared to the last year’s volume of 1.82 million, its volume of 1.13 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 73.86%. Additionally, its Average True Range was 0.58.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 52.74%, which indicates a significant increase from 43.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.24% in the past 14 days, which was higher than the 55.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.99, while its 200-day Moving Average is $8.22. Nevertheless, the first resistance level for the watch stands at $10.00 in the near term. At $10.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.80. If the price goes on to break the first support level at $9.20, it is likely to go to the next support level at $8.90. Now, if the price goes above the second support level, the third support stands at $8.40.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are currently 157,217K shares outstanding in the company with a market cap of 1.49 billion. Presently, the company’s annual sales total 58,440 K according to its annual income of -80,740 K. Last quarter, the company’s sales amounted to 15,430 K and its income totaled -36,490 K.
